The National Research Council of Canada has announced that the Chinese company Cansino Biologics, which is behind one of the few candidate vaccines for treatment of the emerging coronavirus (Covid-19), is already undergoing clinical trials, is cooperating with it to “pave the way” for future trials in Canada.
The Council added that it would support the production of the candidate vaccine Cansino, at a government facility in Montreal, and that the company was submitting an application for clinical trials to the Canadian Health Authority responsible for regulating medicines in the country.
The Chinese company vaccine is still under early testing and there is no way to know whether or not it will work, but if it proves useful, this cooperation may help ensure that Canadians can reach it.
Local trial data can reassure the Canadian Health Ministry that the vaccine is safe and that local manufacturing can guarantee some doses.
This vaccine is produced using a cell line developed in the Canadian National Research Council. The Council and Cansino Corporation have been working together since 2013. The company has used the same cell line to develop an Ebola vaccine.
The Research Council or the Canadian Health Authority has yet to answer questions about whether this cooperation will make it possible for the Canadian Health Authority to consider trial data collected in China in the eventual evaluation of the vaccine.
Follow our latest local and sports news and the latest political and economic developments via Google news